The COVID19 epidemic that broke out at the end of 2019 is still raging around the world. The cause of this epidemic, the SARS-CoV-2, has an astonishing speed of mutation. It took just over a year to use nearly 1/2 of the Greek alphabet, and developed from Alpha to Lambda.
At the end of December 2020, the SARS-CoV-2 variant Alpha was discovered in the United Kingdom, and the epidemic in the United Kingdom suddenly got out of control. Then, South Africa discovered Beta, India discovered Delta, and Peru discovered Lambda.
Aiming at the main variants of the SARS-CoV-2 in the world, CUSABIO has developed and produced a series of high-quality mutant antigens with various tag. Most of these mutant antigens have been validated in bioactivity.
If you are interested in other SARS-CoV-2 variants, you can contact us for customization.
Target | Product Name | Code | Source | Mutation | Tag Info |
---|---|---|---|---|---|
N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K,G204R) (Active) | CSB-EP3325GMY(M12) | E.coli | R203K, G204R | N-terminal 6xHis-tagged |
Target | Product Name | Code | Source | Mutation | Tag Info |
---|---|---|---|---|---|
N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (D63G,R203M,D377Y) (Active) | CSB-EP3325GMY(M14) | E.coli | D63G, R203M, D377Y | N-terminal 6xHis-tagged |
Target | Product Name | Code | Source | Mutation | Tag Info |
---|---|---|---|---|---|
N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203M,D377Y) (Active) | CSB-EP3325GMY(M13) | E.coli | R203M, D377Y | N-terminal 6xHis-tagged |
Target | Product Name | Code | Source | Mutation | Tag Info |
---|---|---|---|---|---|
N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (D3L,R203K,G204R,S235F) (Active) | CSB-EP3325GMY(M1) | E.coli | D3L, R203K, G204R, S235F | N-terminal 6xHis-tagged |
N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K,G204R) (Active) | CSB-EP3325GMY(M12) | E.coli | R203K, G204R | N-terminal 6xHis-tagged |
S1 | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (D614G),partial (Active) | CSB-MP3324GMY(M1) | Mammalian cell | D614G | C-terminal 10xHis-tagged |
S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) | CSB-MP3324GMY1(M6) | Mammalian cell | N501Y | C-terminal 10xHis-tagged |
S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) | CSB-MP3324GMY1(M6)k2 | Mammalian cell | N501Y | C-terminal 6xHis-mFC-tagged |
Target | Product Name | Code | Source | Mutation | Tag Info |
---|---|---|---|---|---|
N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (T205I) (Active) | CSB-EP3325GMY(M2) | E.coli | T205I | N-terminal 6xHis-tagged |
S1 | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (D614G), partial (Active) | CSB-MP3324GMY(M1) | Mammalian cell | D614G | C-terminal 10xHis-tagged |
S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y), partial (Active) | CSB-MP3324GMY1(M6) | Mammalian cell | N501Y | C-terminal 10xHis-tagged |
S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y), partial (Active) | CSB-MP3324GMY1(M6)k2 | Mammalian cell | N501Y | C-terminal 6xHis-mFC-tagged |
Target | Product Name | Code | Source | Mutation | Tag Info |
---|---|---|---|---|---|
N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (P80R) (Active) | CSB-EP3325GMY(M3) | E.coli | P80R | N-terminal 6xHis-tagged |
S1 | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (D614G),partial (Active) | CSB-MP3324GMY(M1) | Mammalian cell | D614G | C-terminal 10xHis-tagged |
S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) | CSB-MP3324GMY1(M6) | Mammalian cell | N501Y | C-terminal 10xHis-tagged |
S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) | CSB-MP3324GMY1(M6)k2 | Mammalian cell | N501Y | C-terminal 6xHis-mFC-tagged |
S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein(S)(E484K),partial | CSB-MP3324GMY1(M8) | Mammalian cell | E484K | C-terminal 10xHis-tagged |
S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein(S) (E484K), partial (Active) | CSB-MP3324GMY1(M8)h8 | Mammalian cell | E484K | C-terminal mFC-tagged |
● Recombinant SARS-CoV-2 Nucleoprotein (N)(R203K,G204R) (Active) (CSB-EP3325GMY(M12))
Its purity is greater than 96% as determined by SDS-PAGE.
Its binding ability measured by functional ELISA with N Mouse Monoclonal Antibody at 2 μg/ml, of which EC50 is 6.775-13.04 ng/ml.
Its binding ability measured by functional ELISA with N Recombinant Antibody at 2 μg/ml, of which EC50 is 4.664-8.256 ng/ml.
● Recombinant SARS-CoV-2 Nucleoprotein (N)(D63G,R203M,D377Y) (Active) (CSB-EP3325GMY(M14))
Its purity is greater than 85.7% as determined by SDS-PAGE.
Its binding ability measured by functional ELISA with N Mouse Monoclonal Antibody at 2 μg/ml, of which EC50 is 3.834 - 5.294 ng/ml.
Its binding ability measured by functional ELISA with N Recombinant Antibody at 2 μg/ml, of which EC50 is 1.304 - 1.875 ng/ml ng/ml.
● Recombinant SARS-CoV-2 Spike glycoprotein(S) (E484K), partial (Active) (CSB-MP3324GMY1(M8)h8)
Its purity is greater than 90% as determined by SDS-PAGE.
Its binding ability measured by functional ELISA with human ACE2 at 2 μg/ml, the EC50 is 6.597-8.187 ng/ml.
Its binding ability measured by functional ELISA with Biotin-S Antibody at 2 μg/ml, the EC50 is 118.7 ng/ml.
SARS-CoV-2 Antibodies & Proteins
SARS-CoV-2 ELISA Kit